novel ecteinascidin derivative 1

Novel ecteinascidin derivative 1 is one of two synthetic derivatives of lurbinectedin developed by researchers at the IGBMC. It is designed to target transcriptional addiction in cancer by inhibiting super-enhancer (SE)-driven oncogenic transcription. The compound works by directly binding to and inhibiting the promoters of genes that encode ubiquitous transcription factors and coactivators enriched at SE sites. In preclinical studies, it has demonstrated potent anti-tumor activity against skin cutaneous melanoma, including models resistant to standard therapies, by reducing tumor growth and prolonging survival.

Other names

synthetic ecteinascidin derivativelurbinectedin derivative